Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06515184 · ClinicalTrials.gov registry record · Phase 3
Coenzyme Q10 for Gulf War Illness: A Replication Study
A Phase 3 study of Gulf War Syndrome and Persian Gulf Syndrome, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 192
- Enrollment target
- 1
- Study location
NCT06515184: Recruiting Phase 3 study of Gulf War Syndrome and Persian Gulf Syndrome, sponsored by University of California, San Diego.
NCT06515184 is a Phase 3 study of Gulf War Syndrome and Persian Gulf Syndrome that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 192 participants, above the 111-participant average among 8 other Gulf War Syndrome trials with a reported enrollment target (73% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06515184, a Phase 3 study of Gulf War Syndrome and Persian Gulf Syndrome, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 192 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess whether a high quality preparation of ubiquinone (coenzyme Q10) benefits symptoms, function, and quality of life in veterans with Gulf War illness.
Primary Outcome
All outcomes are assessed as change from baseline.
Conditions Studied
Interventions
- DRUG PharmaNord Bio-Quinone Active CoQ10 Gold 100mg
- DRUG PharmaNord Placebo
Study Locations (1)
California
- UC San Diego - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2024-09-13 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
What NCT06515184 shows while recruiting
NCT06515184 is an interventional study that assigns participants to a tested intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, above the 111-participant average among 8 other Gulf War Syndrome trials with a reported enrollment target (73% higher).
The record links to 3 conditions, with Gulf War Syndrome appearing as the primary indexed condition, and to 2 interventions - of which PharmaNord Bio-Quinone Active CoQ10 Gold 100mg is the first listed.
NCT06515184 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06515184 about?
NCT06515184 is a clinical study titled "Coenzyme Q10 for Gulf War Illness: A Replication Study". The purpose of this study is to assess whether a high quality preparation of ubiquinone (coenzyme Q10) benefits symptoms, function, and quality of life in veterans with Gulf War illness.
What is the current status of trial NCT06515184?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 192 participants. The study started on 2024-09-13. Estimated completion is 2027-12.
What conditions does trial NCT06515184 study?
This clinical trial studies the following conditions: Gulf War Syndrome, Persian Gulf Syndrome, Mitochondrial Disorder, Respiratory Chain.
What interventions are being tested in trial NCT06515184?
The interventions under investigation include: PharmaNord Bio-Quinone Active CoQ10 Gold 100mg (DRUG), PharmaNord Placebo (DRUG).
Who is sponsoring clinical trial NCT06515184?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06515184 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gulf War Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06515184's enrollment target sits among peer trials
192 2nd of 8 the highest of 8 other Gulf War Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gulf War Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Confirmation of Diet as a Treatment for Gulf War Illness
RECRUITING · Phase 3
-
Clinical Evaluation of Montelukast in Veterans With Gulf War Illness
RECRUITING · Phase 1
-
Validating Gulf War Illness Blood Biomarkers
RECRUITING
-
Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)
RECRUITING · Phase 2
-
Confirming the Effects of Acupuncture Treatments to Relieve Symptoms of Gulf War Illness
RECRUITING · NA
-
GWICTIC: NAC Mechanistic Study in Gulf War Veterans
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
- NCT03622359 · 192 participants · NA
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI